Step therapy vs prior authorization: how the two utilization controls differ

A prescription comes back rejected at the pharmacy. The rejection code says prior authorization required. Your team submits the PA, the payer approves it, and the claim rejects again, this time because the plan wants the patient to try a preferred alternative first. Nothing went wrong procedurally. The prescription simply sat behind two different utilization controls, and clearing one did nothing to clear the other.

Practice staff who treat step therapy and prior authorization as the same thing lose days to exactly this sequence. The two tools ask different questions, demand different documentation, and follow different exception paths. Understanding where they diverge is the difference between one clean submission and a week of resubmissions while the patient waits.

This article defines both controls, compares them side by side, explains how they stack on a single prescription, and walks through the exception processes practice staff use. None of this is clinical guidance. Which drug a patient should take is always a decision for the prescribing provider; this is about getting the payer to cover what the provider ordered.

What prior authorization is

Prior authorization is a payer requirement that a provider obtain approval before a specific service, procedure, or drug will be covered. It is a yes-or-no gate: the payer reviews the request against its medical necessity criteria and either approves, denies, or asks for more information. Until the approval exists, the claim will not pay.

Prior authorization applies broadly. Payers attach it to imaging, surgeries, durable medical equipment, specialty drugs, inpatient admissions, and behavioral health services, among many others. The common thread is that the payer wants to review the clinical justification before agreeing to pay, not after.

The administrative weight is well documented. The American Medical Association's physician surveys have repeatedly found that practices complete dozens of prior authorization requests per physician per week, and that physicians and staff spend many hours each week completing them. The AMA has also reported that most surveyed physicians say prior authorization delays access to necessary care. Those findings are why PA reform keeps appearing in federal rulemaking and state legislation.

If you need a refresher on how prior authorization differs from a referral (another thing it is often confused with), see our comparison of referrals vs prior authorization. And when a service has already been delivered without the approval in hand, the narrow exception path is a retro authorization, which follows its own rules and timelines.

What step therapy is

Step therapy is a payer rule that requires a patient to try one or more preferred drugs, usually lower-cost generics or preferred-formulary brands, before the plan will cover the drug the provider prescribed. It is sometimes called "fail first," because coverage of the prescribed drug typically unlocks only after the preferred options have failed, caused intolerable side effects, or been ruled out as inappropriate.

Where prior authorization asks "is this medically necessary," step therapy asks "has the patient tried what we prefer first." It is a sequencing control, not an approval gate. The payer is not necessarily disputing that the prescribed drug is appropriate; it is asserting that a cheaper alternative should be attempted before the more expensive one is covered.

Step therapy shows up most often in drug categories with multiple therapeutic options at very different price points: biologics for autoimmune conditions, newer diabetes and weight management drugs, specialty dermatology agents, migraine preventives, and many psychiatric medications. Behavioral health prescriptions run into step edits frequently, which is one reason behavioral health prior authorization workflows deserve their own playbook.

Medicare Advantage plans may apply step therapy to certain physician-administered Part B drugs under CMS policy, subject to protections such as exemptions for patients already stable on a drug. Commercial plans and Medicaid managed care plans set their own step therapy protocols within the limits of applicable state and federal rules.

Side-by-side comparison

The last row matters and is worth restating plainly: neither control changes what the provider may prescribe. Both determine only what the plan will pay for, and both have formal paths for the provider to assert that the prescribed therapy should be covered as written.

How the two controls stack on the same prescription

Payers layer utilization controls, and specialty drugs commonly carry both. A biologic might require prior authorization and sit behind a two-step edit. In practice that means the PA form itself asks which preferred agents the patient has tried, for how long, and with what outcome. The step therapy requirement is embedded inside the prior authorization review.

Three practical consequences follow:

1. Clearing one control does not clear the other. An approved PA for a drug can still hit a step edit at the pharmacy if the step logic lives in the pharmacy benefit rather than the PA. Check both before telling the patient the drug is approved.
2. The denial reason tells you which control fired. A denial citing "criteria not met" is usually a medical necessity problem. A rejection citing "formulary alternative required" or a step edit code is a sequencing problem. The fix is different for each, so read the code before rebuilding the submission. Our breakdown of common prior authorization denial reasons covers how to decode these quickly.
3. Documentation gathered once serves both. A complete record of prior drug trials, dates, doses, durations, and outcomes satisfies the step therapy questions inside a PA and stands alone as an override request. Capture it once, structured, and reuse it.

Medical and pharmacy benefits complicate the picture further. Physician-administered drugs often run through the medical benefit with its own PA process, while self-administered versions of similar therapies run through the pharmacy benefit with formulary step edits. When a drug could route either way, confirm which benefit applies before submitting anything, or you will complete the wrong payer's process perfectly.

Requesting a step therapy exception or override

Every plan that uses step therapy maintains an exception process, and many states require insurers to grant exceptions under defined circumstances and within defined timeframes. The grounds that most commonly succeed are consistent across payers:

1. Prior failure. The patient already tried the required step drug (on this plan or a previous one) and it did not work. Document the drug, dose, duration, and the clinical outcome.
2. Intolerance or adverse reaction. The patient tried the step drug and experienced side effects that forced discontinuation. Document what occurred and when.
3. Contraindication. The step drug is expected to be ineffective or harmful given the patient's condition, comorbidities, or interactions with current medications, per the prescribing provider's judgment.
4. Current stability. The patient is already stable on the prescribed drug, often from a prior plan or a hospital discharge, and switching would risk the patient's condition. Many plans and several state laws treat forced switching of stable patients as grounds for an exception.

A strong exception request reads like a compact medical necessity argument: what was tried, what happened, why the alternatives are inappropriate, and why the prescribed drug is the right coverage decision. The same skills that produce a persuasive medical necessity letter for prior authorization produce a persuasive step therapy override, and practices should template both.

If the exception is denied, the request converts into a standard appeal with the plan's normal levels: internal review, then external review where applicable. Urgent situations qualify for expedited review under most plans' rules; say so explicitly on the request when the provider judges the standard timeline would jeopardize the patient.

Where state regulation fits

Step therapy has drawn sustained legislative attention, and a majority of states have enacted some form of step therapy reform law. These laws vary, but they commonly require insurers to publish clear exception criteria, respond to exception requests within set timeframes (often faster for urgent requests), and grant exceptions in circumstances like documented prior failure or clinical stability on the current drug.

Two cautions for practice staff. First, state laws generally apply to state-regulated plans; self-funded employer plans governed by federal law are typically outside their reach, so two patients with the same drug and same payer logo can face different rules. Second, the specifics differ enough between states that your appeal letter should cite the plan's own published exception policy first and the state framework second. When in doubt about what a particular state requires, verify against the state insurance department's published guidance rather than assuming.

The practical takeaway is not to memorize statutes. It is that exception processes are not a courtesy; in many markets they are an obligation, and a well-documented request that goes unanswered past the required timeframe is itself grounds for escalation.

Operational playbook for practice staff

Practices that handle both controls cleanly tend to run the same core workflow:

1. Check both controls at ordering time. When a prescription or order is placed, verify PA requirements and formulary step status together, not sequentially after the first rejection. Most payer portals and e-prescribing systems surface formulary alternatives and PA flags at the point of ordering.
2. Capture drug history in structured fields. Prior trials, doses, durations, and outcomes belong in discrete fields, not buried in narrative notes. This is the raw material for every step override and most drug PAs.
3. Template the exception request. Build one template per common drug class with the payer's exception criteria as headings. Staff fill in patient specifics rather than drafting from scratch.
4. Read rejection codes before resubmitting. Route medical necessity denials to the PA appeal path and step edits to the override path. Sending a medical necessity letter in response to a step edit wastes a cycle.
5. Track timeframes. Log when each request went in and when the plan's response clock expires. Escalate the day it lapses.
6. Tell the patient which gate they are behind. "Your insurance wants records of the drugs you tried before" is a different conversation than "your insurance is reviewing whether it will cover this," and setting the right expectation reduces inbound calls.

Teams that adopt prior authorization automation remove most of the manual burden from this workflow: eligibility and PA requirements checked automatically at intake, documentation assembled from the chart, and submissions tracked against payer clocks without a coordinator watching a spreadsheet.

The bottom line

Prior authorization is an approval gate; step therapy is a sequencing rule. Prior authorization asks whether the service or drug is medically necessary under plan criteria. Step therapy asks whether the plan's preferred alternatives were tried first. They are administered separately, they fail separately, and they are appealed separately, yet they routinely stack on the same prescription, especially for specialty drugs.

For practice staff, the operational answer is to treat them as two checkboxes on one intake step: verify both at ordering, keep drug trial history structured and reusable, read the rejection code before choosing the response, and hold payers to their published exception timeframes. The prescribing provider decides the therapy; your job is to make the coverage decision catch up to it as fast as possible.

Frequently asked questions

Sources

• CMS, Medicare Advantage prior authorization and step therapy for Part B drugs
• American Medical Association, prior authorization research and reports
• CAQH Index, administrative transaction cost and automation benchmarks